OHR Pharmaceutical Inc - Company & Market Research Reports

Ohr Pharmaceutical is a pharmaceutical company focused on the development of novel therapeutics for the treatment of ocular diseases. Its lead clinical program is its OHR-102 (Squalamine) eye drops, a small molecule anti-angiogenic drug that provides a non-invasive therapy to enhance vision. It could be used in the treatment of retinal diseases, including wet age related macular degeneration (AMD), retinal vein occlusion and diabetic retinopathy. OHR Pharmaceutical is headquartered in New York.

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities - Product Thumbnail Image

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities

  • Report
  • 144 Pages
Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
Diabetic Macular Edema - Pipeline Review, H2 2018 - Product Thumbnail Image

Diabetic Macular Edema - Pipeline Review, H2 2018

  • Drug Pipelines
  • 231 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Allergic Conjunctivitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Allergic Conjunctivitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 78 Pages
From
Allergic Conjunctivitis - Pipeline Review, H2 2017 - Product Thumbnail Image

Allergic Conjunctivitis - Pipeline Review, H2 2017

  • Drug Pipelines
  • 70 Pages
From
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2018 - Product Thumbnail Image

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2018

  • Drug Pipelines
  • 52 Pages
From
Diabetic Retinopathy - Pipeline Review, H1 2018 - Product Thumbnail Image

Diabetic Retinopathy - Pipeline Review, H1 2018

  • Drug Pipelines
  • 219 Pages
From
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018 - Product Thumbnail Image

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 52 Pages
From
Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026 - Product Thumbnail Image

Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026

  • Report
  • 228 Pages
From
Glaucoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 299 Pages
From
Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview  - Product Thumbnail Image

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

  • Report
  • 208 Pages
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
Glaucoma - Pipeline Review, H2 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H2 2018

  • Drug Pipelines
  • 308 Pages
From
Wet Age-related Macular Degeneration - Pipeline Insights, 2017 - Product Thumbnail Image

Wet Age-related Macular Degeneration - Pipeline Insights, 2017

  • Drug Pipelines
  • 106 Pages
From
Retinal Vein Occlusion - Pipeline Review, H1 2018 - Product Thumbnail Image

Retinal Vein Occlusion - Pipeline Review, H1 2018

  • Drug Pipelines
  • 106 Pages
From
Age Related Macular Degeneration - Pipeline Review, H2 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H2 2017

  • Drug Pipelines
  • 537 Pages
From
Age Related Macular Degeneration - Pipeline Review, H1 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2017

  • Drug Pipelines
  • 527 Pages
From
Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

  • Report
  • 319 Pages
From
Loading Indicator
adroll